Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy

Background—Myocardial late gadolinium enhancement (LGE) on contrast-enhanced magnetic resonance imaging (CE-MRI) of patients with hypertrophic cardiomyopathy (HCM) has been suggested to represent intramyocardial fibrosis and, as such, an adverse prognostic risk factor. We evaluated the characteristics of LGE on CE-MRI and explored whether LGE among patients with HCM was associated with genetic testing, severe symptoms, ventricular arrhythmias, or sudden cardiac death (SCD). Methods and Results—Four hundred twenty-four patients with HCM (age=55±16 years [range 2 to 90], 41% females), without a history of septal ablation/myectomy, underwent CE-MRI (GE 1.5 Tesla). We evaluated the relation between LGE and HCM genes status, severity of symptoms, and the degree of ventricular ectopy on Holter ECG. Subsequent SCD and appropriate implanted cardioverter defibrillator (ICD) therapies were recorded during a mean follow-up of 43±14 months (range 16 to 94). Two hundred thirty-nine patients (56%) had LGE on CE-MRI, ranging from 0.4% to 65% of the left ventricle. Gene-positive patients were more likely to have LGE (P<0.001). The frequencies of New York Heart Association class ≥3 dyspnea and angina class ≥3 were similar in patients with and without LGE (125 of 239 [52%] versus 94 of 185 [51%] and 24 of 239 [10%] versus 18 of 185 [10%], respectively, P=NS). LGE-positive patients were more likely to have episodes of nonsustained ventricular tachycardia (34 of 126 [27%] versus 8 of 94 [8.5%], P<0.001), had more episodes of nonsustained ventricular tachycardia per patient (4.5±12 versus 1.1±0.3, P=0.04), and had higher frequency of ventricular extrasystoles/24 hours (700±2080 versus 103±460, P=0.003). During follow-up, SCD occurred in 4 patients, and additional 4 patients received appropriate ICD discharges. All 8 patients were LGE positive (event rate of 0.94%/y, P=0.01 versus LGE negative). Two additional heart failure-related deaths were recorded among LGE-positive patients. Univariate associates of SCD or appropriate ICD discharge were positive LGE (P=0.002) and presence of nonsustained ventricular tachycardia (P=0.04). The association of LGE with events remained significant after controlling for other risk factors. Conclusions—In patients with HCM, presence of LGE on CE-MRI was common and more prevalent among gene-positive patients. LGE was not associated with severe symptoms. However, LGE was strongly associated with surrogates of arrhythmia and remained a significant associate of subsequent SCD and/or ICD discharge after controlling for other variables. If replicated, LGE may be considered an important risk factor for sudden death in patients with HCM.

[1]  B. Gersh,et al.  Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy , 2009, Heart.

[2]  Warren J Manning,et al.  Clinical Profile and Significance of Delayed Enhancement in Hypertrophic Cardiomyopathy , 2008, Circulation. Heart failure.

[3]  B. Gersh,et al.  Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy , 2008, Circulation.

[4]  S. Ommen,et al.  Relationship between sex, shape, and substrate in hypertrophic cardiomyopathy. , 2008, American heart journal.

[5]  W. Manning,et al.  Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. , 2008, Journal of the American College of Cardiology.

[6]  K. Takeda,et al.  Correlation between late gadolinium enhancement and diastolic function in hypertrophic cardiomyopathy assessed by magnetic resonance imaging. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[7]  W. Roberts,et al.  Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. , 2008, The American journal of cardiology.

[8]  V. Fuster,et al.  Risk stratification of sudden cardiac death in hypertrophic cardiomyopathy , 2007, Nature Clinical Practice Cardiovascular Medicine.

[9]  A. Tajik,et al.  Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. , 2007, European heart journal.

[10]  B. Gersh,et al.  Surgery Insight: septal myectomy for obstructive hypertrophic cardiomyopathy—the Mayo Clinic experience , 2007, Nature Clinical Practice Cardiovascular Medicine.

[11]  L. Harris,et al.  Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy , 2007, Heart.

[12]  S. Ommen,et al.  Hypertrophic cardiomyopathy, sudden death, and implantable cardiac defibrillators: how low the bar? , 2007, JAMA.

[13]  M. Link,et al.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.

[14]  P. Elliott,et al.  Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. , 2007, Journal of the American College of Cardiology.

[15]  H. Sakahara,et al.  Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy. , 2007, Journal of cardiac failure.

[16]  N. Bellenger,et al.  Ischaemic and non-ischaemic cardiomyopathies--cardiac MRI appearances with delayed enhancement. , 2007, Clinical radiology.

[17]  A. Tajik,et al.  Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. , 2007, Journal of the American College of Cardiology.

[18]  C. Kramer The expanding prognostic role of late gadolinium enhanced cardiac magnetic resonance. , 2006, Journal of the American College of Cardiology.

[19]  Dudley J Pennell,et al.  Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[20]  W. Stevenson,et al.  Characterization of the Peri-Infarct Zone by Contrast-Enhanced Cardiac Magnetic Resonance Imaging Is a Powerful Predictor of Post–Myocardial Infarction Mortality , 2006, Circulation.

[21]  Roger B. Davis,et al.  Impact of Unrecognized Myocardial Scar Detected by Cardiac Magnetic Resonance Imaging on Event-Free Survival in Patients Presenting With Signs or Symptoms of Coronary Artery Disease , 2006, Circulation.

[22]  L. Monserrat,et al.  Magnetic Resonance Imaging of Delayed Enhancement in Hypertrophic Cardiomyopathy: Relationship with Left Ventricular Perfusion and Contractile Function , 2006, Journal of computer assisted tomography.

[23]  Michael J Ackerman,et al.  Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. , 2006, Mayo Clinic proceedings.

[24]  C. Rochitte,et al.  The emerging role of MRI in the diagnosis and management of cardiomyopathies , 2006, Current cardiology reports.

[25]  R. Gibbons,et al.  Prognostic utility of single-photon emission computed tomography in adult patients with hypertrophic cardiomyopathy. , 2006, American heart journal.

[26]  M. Link,et al.  Significance and relation between magnitude of left ventricular hypertrophy and heart failure symptoms in hypertrophic cardiomyopathy. , 2005, The American journal of cardiology.

[27]  C. Autore,et al.  The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. , 2005, Journal of the American College of Cardiology.

[28]  P. Elliott,et al.  Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.

[29]  Heiko Mahrholdt,et al.  Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[30]  B. Maron Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[31]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[32]  O. Simonetti,et al.  The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. , 2000, The New England journal of medicine.

[33]  W J McKenna,et al.  Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease , 2000, Heart.

[34]  G Thiene,et al.  Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. , 2000, Human pathology.

[35]  W. Mckenna,et al.  The management of hypertrophic cardiomyopathy. , 1997, The New England journal of medicine.

[36]  K. Bailey,et al.  Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. , 1995, Circulation.

[37]  R. Bonow,et al.  Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). , 1987, The New England journal of medicine.

[38]  W. McKenna,et al.  The natural history of hypertrophic cardiomyopathy. , 1981, Cardiovascular clinics.

[39]  O. Simonetti,et al.  An improved MR imaging technique for the visualization of myocardial infarction. , 2001, Radiology.

[40]  W. Roberts,et al.  Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. , 2000, Journal of the American College of Cardiology.